Tiziana Life Sciences' Shares Rally As Foralumab Shows Encouraging Action In COVID-19 Study In Brazil

Tiziana Life Sciences Plc (NASDAQ: TLSA) surges on the heels of positive data reported from an exploratory study in Brazil, evaluating nasally administered Foralumab, either alone or in combination with orally administered dexamethasone (Dexa) in COVID-19 patients.
The study showed that direct nasal delivery of Foralumab rapidly suppresses lung inflammation and improves senses of smell and taste in treated patients.
Foralumab treated patients showed reduced systemic biomarkers of inflammation, such as the levels of Interleukins-6 and c-reactive protein, compared to patients in the control cohort.
Tiziana says that the treatment may potentially be useful in other emerging variants of COVID-19, and nasal administration of foralumab can be possible in-home settings as well.
Price Action: TLSA shares gained 43.7% at $5.49 in the pre-market session on the last check Tuesday.